Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

The pathological upgrading after radical prostatectomy in low-risk prostate cancer patients who are eligible for active surveillance: How safe is it to depend on bioptic pathology?

Verep S, Erdem S, Ozluk Y, Kilicaslan I, Sanli O, Ozcan F.

Prostate. 2019 Jul 3. doi: 10.1002/pros.23873. [Epub ahead of print]

PMID:
31269285
2.

Cribriform morphology predicts upstaging after radical prostatectomy in patients with Gleason score 3 + 4 = 7 prostate cancer at transrectal ultrasound (TRUS)-guided needle biopsy.

Keefe DT, Schieda N, El Hallani S, Breau RH, Morash C, Robertson SJ, Mai KT, Belanger EC, Flood TA.

Virchows Arch. 2015 Oct;467(4):437-42. doi: 10.1007/s00428-015-1809-5. Epub 2015 Jul 31.

PMID:
26229020
3.

Utility of Gleason pattern 4 morphologies detected on transrectal ultrasound (TRUS)-guided biopsies for prediction of upgrading or upstaging in Gleason score 3 + 4 = 7 prostate cancer.

Flood TA, Schieda N, Keefe DT, Breau RH, Morash C, Hogan K, Belanger EC, Mai KT, Robertson SJ.

Virchows Arch. 2016 Sep;469(3):313-9. doi: 10.1007/s00428-016-1981-2. Epub 2016 Jul 10.

PMID:
27394432
4.

Clinical and pathologic predictors of Gleason sum upgrading in patients after radical prostatectomy: results from a single institution series.

Tilki D, Schlenker B, John M, Buchner A, Stanislaus P, Gratzke C, Karl A, Tan GY, Ergün S, Tewari AK, Stief CG, Seitz M, Reich O.

Urol Oncol. 2011 Sep-Oct;29(5):508-14. doi: 10.1016/j.urolonc.2009.07.003. Epub 2009 Oct 17.

PMID:
19837614
5.

Postoperative upgrading of prostate cancer in men ≥75 years: a propensity score-matched analysis.

Herlemann A, Buchner A, Kretschmer A, Apfelbeck M, Stief CG, Gratzke C, Tritschler S.

World J Urol. 2017 Oct;35(10):1517-1524. doi: 10.1007/s00345-017-2045-1. Epub 2017 May 10.

PMID:
28493044
6.

Heterogeneity in D'Amico classification-based low-risk prostate cancer: Differences in upgrading and upstaging according to active surveillance eligibility.

Schiffmann J, Wenzel P, Salomon G, Budäus L, Schlomm T, Minner S, Wittmer C, Kraft S, Krech T, Steurer S, Sauter G, Beyer B, Boehm K, Tilki D, Michl U, Huland H, Graefen M, Karakiewicz PI.

Urol Oncol. 2015 Jul;33(7):329.e13-9. doi: 10.1016/j.urolonc.2015.04.004. Epub 2015 May 7.

PMID:
25960411
7.

Prostate-specific antigen vs prostate-specific antigen density as a predictor of upgrading in men diagnosed with Gleason 6 prostate cancer by contemporary multicore prostate biopsy.

Oh JJ, Hong SK, Lee JK, Lee BK, Lee S, Kwon OS, Byun SS, Lee SE.

BJU Int. 2012 Dec;110(11 Pt B):E494-9. doi: 10.1111/j.1464-410X.2012.11182.x. Epub 2012 Apr 30.

8.

Preoperative characteristics of high-Gleason disease predictive of favourable pathological and clinical outcomes at radical prostatectomy.

Pierorazio PM, Ross AE, Lin BM, Epstein JI, Han M, Walsh PC, Partin AW, Pavlovich CP, Schaeffer EM.

BJU Int. 2012 Oct;110(8):1122-8. doi: 10.1111/j.1464-410X.2012.10986.x. Epub 2012 Feb 28.

9.

Population based study of predictors of adverse pathology among candidates for active surveillance with Gleason 6 prostate cancer.

Vellekoop A, Loeb S, Folkvaljon Y, Stattin P.

J Urol. 2014 Feb;191(2):350-7. doi: 10.1016/j.juro.2013.09.034. Epub 2013 Sep 23.

PMID:
24071481
10.

Pathological upgrading in prostate cancer patients eligible for active surveillance: Does prostate-specific antigen density matter?

Jin BS, Kang SH, Kim DY, Oh HG, Kim CI, Moon GH, Kwon TG, Park JS.

Korean J Urol. 2015 Sep;56(9):624-9. doi: 10.4111/kju.2015.56.9.624. Epub 2015 Sep 2.

11.

Perineural invasion on biopsy is associated with upstaging at radical prostatectomy in Gleason score 3 + 4 = 7 prostate cancer.

Flood TA, Schieda N, Keefe DT, Morash C, Bateman J, Mai KT, Belanger EC, Robertson SJ, Breau RH.

Pathol Int. 2016 Nov;66(11):629-632. doi: 10.1111/pin.12467. Epub 2016 Oct 5.

PMID:
27709739
12.

Role of PSA velocity in predicting pathologic upgrade for Gleason 6 prostate cancer.

Krane LS, Menon M, Kaul SA, Siddiqui SA, Wambi C, Peabody JO, Agarwal PK.

Urol Oncol. 2011 Jul-Aug;29(4):372-7. doi: 10.1016/j.urolonc.2009.04.018. Epub 2009 Jul 3.

PMID:
19576796
13.

Risk of Upgrading and Upstaging Among 10 000 Patients with Gleason 3+4 Favorable Intermediate-risk Prostate Cancer.

Yang DD, Mahal BA, Muralidhar V, Nezolosky MD, Vastola ME, Labe SA, Boldbaatar N, King MT, Martin NE, Orio PF 3rd, Beard CJ, Hoffman KE, Trinh QD, Spratt DE, Feng FY, Nguyen PL.

Eur Urol Focus. 2019 Jan;5(1):69-76. doi: 10.1016/j.euf.2017.05.011. Epub 2017 Jun 17.

PMID:
28753811
14.

Does cumulative prostate cancer length (CCL) in prostate biopsies improve prediction of clinically insignificant cancer at radical prostatectomy in patients eligible for active surveillance?

Chen DJ, Falzarano SM, McKenney JK, Przybycin CG, Reynolds JP, Roma A, Jones JS, Stephenson A, Klein E, Magi-Galluzzi C.

BJU Int. 2015 Aug;116(2):220-9. doi: 10.1111/bju.12880. Epub 2014 Dec 15.

15.

Is transperineal prostate biopsy more accurate than transrectal biopsy in determining final Gleason score and clinical risk category? A comparative analysis.

Scott S, Samaratunga H, Chabert C, Breckenridge M, Gianduzzo T.

BJU Int. 2015 Oct;116 Suppl 3:26-30. doi: 10.1111/bju.13165. Epub 2015 Aug 11.

16.

Pathologic Outcomes of Gleason 6 Favorable Intermediate-Risk Prostate Cancer Treated With Radical Prostatectomy: Implications for Active Surveillance.

Yang DD, Mahal BA, Muralidhar V, Vastola ME, Boldbaatar N, Labe SA, Nezolosky MD, Orio PF 3rd, King MT, Martin NE, Mouw KW, Trinh QD, Nguyen PL.

Clin Genitourin Cancer. 2018 Jun;16(3):226-234. doi: 10.1016/j.clgc.2017.10.013. Epub 2017 Nov 9.

PMID:
29196209
17.

Prediction of Gleason score upgrading in low-risk prostate cancers diagnosed via multi (> or = 12)-core prostate biopsy.

Hong SK, Han BK, Lee ST, Kim SS, Min KE, Jeong SJ, Jeong H, Byun SS, Lee HJ, Choe G, Lee SE.

World J Urol. 2009 Apr;27(2):271-6. doi: 10.1007/s00345-008-0343-3. Epub 2008 Nov 20.

PMID:
19020885
18.

The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume.

Corcoran NM, Casey RG, Hong MK, Pedersen J, Connolly S, Peters J, Harewood L, Gleave ME, Costello AJ, Hovens CM, Goldenberg SL.

BJU Int. 2012 Jul;110(1):36-42. doi: 10.1111/j.1464-410X.2011.10681.x. Epub 2011 Nov 15.

19.

Preoperative prostate-specific antigen isoform p2PSA and its derivatives, %p2PSA and prostate health index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer.

Guazzoni G, Lazzeri M, Nava L, Lughezzani G, Larcher A, Scattoni V, Gadda GM, Bini V, Cestari A, Buffi NM, Freschi M, Rigatti P, Montorsi F.

Eur Urol. 2012 Mar;61(3):455-66. doi: 10.1016/j.eururo.2011.10.038. Epub 2011 Nov 4.

PMID:
22078333
20.

Risk of Pathologic Upgrading or Locally Advanced Disease in Early Prostate Cancer Patients Based on Biopsy Gleason Score and PSA: A Population-Based Study of Modern Patients.

Caster JM, Falchook AD, Hendrix LH, Chen RC.

Int J Radiat Oncol Biol Phys. 2015 Jun 1;92(2):244-51. doi: 10.1016/j.ijrobp.2015.01.051. Epub 2015 Apr 1.

PMID:
25841621

Supplemental Content

Support Center